Antonio Craxi
Antonio Craxi
Full Professor of Gastroenterology and Internal Medicine
Verified email at unipa.it
Title
Cited by
Cited by
Year
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
MW Fried, ML Shiffman, KR Reddy, C Smith, G Marinos, FL Gonēales Jr, ...
New England Journal of Medicine 347 (13), 975-982, 2002
81222002
EASL Clinical Practice Guidelines: management of hepatitis C virus infection
European Association For The Study Of The Liver
J hepatol 55, 245-264, 2011
20832011
Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
GL Davis, R Esteban-Mur, V Rustgi, J Hoefs, SC Gordon, C Trepo, ...
New England journal of medicine 339 (21), 1493-1499, 1998
15221998
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
S Blach, S Zeuzem, M Manns, I Altraif, AS Duberg, DH Muljono, I Waked, ...
The lancet Gastroenterology & hepatology 2 (3), 161-176, 2017
9992017
Preoperative radiotherapy for resectable rectal cancer: a meta-analysis
C Cammą, M Giunta, F Fiorica, L Pagliaro, A Craxģ, M Cottone
Jama 284 (8), 1008-1015, 2000
9812000
Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials
C Camma, F Schepis, A Orlando, M Albanese, L Shahied, F Trevisani, ...
Radiology 224 (1), 47-54, 2002
9312002
Statements from the Taormina expert meeting on occult hepatitis B virus infection
G Raimondo, JP Allain, MR Brunetto, MA Buendia, DS Chen, M Colombo, ...
Journal of hepatology 49 (4), 652-657, 2008
9262008
Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis
F Fiorica, D Di Bona, F Schepis, A Licata, L Shahied, A Venturi, AM Falchi, ...
Gut 53 (7), 925-930, 2004
6642004
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial
J Bruix, JL Raoul, M Sherman, V Mazzaferro, L Bolondi, A Craxi, PR Galle, ...
Journal of hepatology 57 (4), 821-829, 2012
6532012
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin
P Ferenci, MW Fried, ML Shiffman, CI Smith, G Marinos, FL Gonēales Jr, ...
Journal of hepatology 43 (3), 425-433, 2005
6422005
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised …
IM Jacobson, GJ Dore, GR Foster, MW Fried, M Radu, VV Rafalsky, ...
The Lancet 384 (9941), 403-413, 2014
5882014
Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening
V Ratziu, SA Harrison, S Francque, P Bedossa, P Lehert, L Serfaty, ...
Gastroenterology 150 (5), 1147-1159. e5, 2016
5582016
Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C
S Petta, C Cammą, C Scazzone, C Tripodo, V Di Marco, A Bono, D Cabibi, ...
Hepatology 51 (4), 1158-1167, 2010
5042010
Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection
T Pollicino, G Squadrito, G Cerenzia, I Cacciola, G Raffa, A Craxı̀, ...
Gastroenterology 126 (1), 102-110, 2004
4782004
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection?
F Schepis, C Cammą, D Niceforo, A Magnano, S Pallio, M Cinquegrani, ...
Hepatology 33 (2), 333-338, 2001
4722001
Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach
C Cammą, M Giunta, P Andreone, A Craxı̀
Journal of hepatology 34 (4), 593-602, 2001
4602001
Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: a case-control study
RG Simonetti, C Cammą, F Fiorello, M Cottone, M Rapicetta, L Marino, ...
Annals of internal medicine 116 (2), 97-102, 1992
4371992
Non-alcoholic fatty liver disease pathogenesis: the present and the future
S Petta, C Muratore, A Craxi
Digestive and Liver Disease 41 (9), 615-625, 2009
3772009
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
D Razavi-Shearer, I Gamkrelidze, MH Nguyen, DS Chen, P Van Damme, ...
The lancet Gastroenterology & hepatology 3 (6), 383-403, 2018
3592018
A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma
G Cabibbo, M Enea, M Attanasio, J Bruix, A Craxģ, C Cammą
Hepatology 51 (4), 1274-1283, 2010
3512010
The system can't perform the operation now. Try again later.
Articles 1–20